title: Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.
abstract: OBJECTIVE
  To assess whether ursolic acid (UA) can attenuate lipopolysachharide (LPS)-induced acute lung injury and improve the survival time in a mouse model.
  
  
  METHODS
  The mice were challenged with LPS and survival time was monitored from 0-96 h after LPS treatment. TNF-α, IL-6, IL-1β, HMGB1, nitric oxide (NO) and IL-10 concentration in serum were measured by ELISA. Myeloperoxidase activity, malondialdehyde, lung wet:dry weight ratio and lung permeability in lung tissues were detected. NF-κB, HMGB1 and inducible NO synthase in the lungs were detected by western blot.
  
  
  RESULTS
  UA markedly rescued lethality, improved survival time and lung pathological changes, inhibited TNF-α, IL-6, IL-1β, HMGB1 and NO, and increased IL-10 expression. In addition, UA can also decrease myeloperoxidase, malondialdehyde, lung wet:dry weight ratio and lung permeability. UA attenuated NF-κB, HMGB1 and inducible NO synthase protein expression in the lungs.
  
  
  CONCLUSIONS
  The results suggest that UA is capable of improving survival time and LPS-induced acute lung injury. UA has a potentially therapeutic role in septic shock.
authors.affiliation: State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 1# Keyuan Road 4, Gao-peng Street, High Technological Development Zone, Chengdu, 610041, PR China.
authors.forename: Xiangjun
authors.initials: X
authors.lastname: Chen
authors.forename: Yang
authors.initials: Y
authors.lastname: Wan
authors.forename: Taoyou
authors.initials: T
authors.lastname: Zhou
authors.forename: Jiong
authors.initials: J
authors.lastname: Li
authors.forename: Yuquan
authors.initials: Y
authors.lastname: Wei
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D008168:Lung / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000378:metabolism; D012772:Shock, Septic / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome; D014315:Triterpenes / Q000627:therapeutic use*; D000097245:Ursolic Acid
chemical_list: D000890:Anti-Infective Agents; D016207:Cytokines; D008070:Lipopolysaccharides; D009569:Nitric Oxide; D014315:Triterpenes; D000097245:Ursolic Acid